Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319184 | 0.93 | C3AR1 (0.52) | C3AR1LMNAPOLBTACR1HPGD | |
| Trifluoroacetic Acid SCHEMBL8528372 | 0.86 | NPY4R (0.50) | C3AR1LMNAPOLBTACR1 | |
| SCHEMBL1568736 | 0.86 | C3AR1 (0.83) | C3AR1FNTAFNTBPGGT1BFOLH1 | |
| SCHEMBL1568729 | 0.86 | C3AR1 (0.83) | C3AR1FNTAFNTBPGGT1BFOLH1 | |
| SCHEMBL8064045 | 0.85 | C3AR1 (0.55) | C3AR1FNTAFNTBPGGT1B | |
| SCHEMBL9058352 | 0.84 | NPY4R (0.57) | — | |
| SCHEMBL10277213 | 0.84 | C3AR1 (0.53) | C3AR1HPGDSHMT1 | |
| SCHEMBL4407484 | 0.84 | C3AR1 (0.53) | C3AR1HPGDSHMT1 | |
| SCHEMBL29697124 | 0.82 | C3AR1 (0.52) | C3AR1FNTAFNTBPGGT1BFOLH1 | |
| SCHEMBL30139852 | 0.81 | C3AR1 (0.51) | C3AR1FOLH1SHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040053864-A1 | Methods and compositions for control of bone formation via modulation of neuropeptide y activity | BAYLOR COLLEGE OF MEDICINE | 2004-03-18 | — | — | US | disclosed |
| EP-1017672-B1 | NEW NPY ANTAGONISTS | ASTRAZENECA AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001053477-A1 | METHODS AND COMPOSITIONS FOR CONTROL OF BONE FORMATION VIA MODULATION OF NEUROPEPTIDE Y ACTIVITY | BAYLOR COLLEGE OF MEDICINE (US) | 2001-07-26 | — | — | WO | disclosed |
| US-6127414-A | NPY antagonists | ASTRA AKTIEBOLAG (SE) | 2000-10-03 | — | — | US | disclosed |
| EP-1017672-A1 | NEW NPY ANTAGONISTS | AstraZeneca AB (SE) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999063990-A1 | NEW USE | ASTRAZENECA AB (SE) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999018948-A1 | NEW USE OF NPY ANTAGONISTS | ASTRA AKTIEBOLAG (SE) | 1999-04-22 | — | — | WO | disclosed |
| WO-1999015498-A1 | NEW NPY ANTAGONISTS | ASTRAZENECA AB (SE) | 1999-04-01 | — | — | WO | disclosed |